Author: Ravi Shankar

Louvain-La-Neuve, Belgium, September 29, 2026 at 7 a.m. CEST – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract with the Istituti Fisioterapici Ospitalieri & Istituto Nazionale Tumori Regina Elena (IFO), to provide a turnkey proton therapy solution in Rome, Italy. The center will be the first gantry-based proton therapy system available in central and southern Italy.

Following a rigorous public tender process, IBA and its partners Cecchini SRL and Gowen SRL, construction companies and RTI (Temporary Grouping of Companies) members, have been selected by IFO to deliver a turnkey compact gantry-based Proteus^®ONE¹ system at the Istituti Fisioterapici Ospitalieri center in Rome. IFO will use proton therapy treatment modality for both pediatric and adult patients. As proton therapy is not currently available in central or southern Italy, this landmark project will bring the latest and most widely used gantry-based proton therapy technology with proven high clinical versatility to Italian patients. IFO expects to start treating patients in 2030.

The contract includes the supply of the latest-generation proton therapy system, Proteus^®ONE, design, build, installation, and a comprehensive training & education program as well as a one-year operation and maintenance agreement. As the market-leading compact proton therapy solution, Proteus^®ONE is designed to continuously evolve and integrate the latest technological advancements, enabling IBA users to benefit from cutting-edge innovation and adaptable capabilities.

Henri de Romrée, Deputy Chief Executive Officer of IBA, commented: “We are proud to partner with IFO on this landmark project, which will make gantry-based proton therapy available to patients in central and southern Italy for the first time. With Proteus^®ONE, IBA brings a proven, compact gantry solution designed to broaden access to advanced cancer care and support the treatment of a wide range of clinical indications. This collaboration reflects our shared commitment to bringing innovative, high-quality cancer treatments closer to patients.”

Giuseppe Navanteri, Chief Clinical Engineering and Technology officer of IFO, added: “We are pleased to work with IBA to bring proton therapy closer to patients in our region. We are convinced that choosing a gantry-based solution will provide the clinical versatility needed, enabling more patients to benefit from the advantages of proton therapy. This project represents an important step forward in expanding access to advanced cancer care in central and southern Italy.”

The typical end user price of a Proteus^®️ONE system with a multiyear maintenance contract ranges between €35 and €45 million.

***ENDS***

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered one of the most advanced forms of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals, and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,300 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com.

About IFO

The Istituti Fisioterapici Ospitalieri (IFO) of Rome is one of Italy’s leading public research hospitals and comprises two Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS): the Regina Elena National Cancer Institute (IRE), dedicated to oncology, and the San Gallicano Dermatological Institute (ISG), specialized in dermatology. Founded in 1939, IFO combines patient care, clinical research, education, and innovation, serving as a national and international reference center for cancer treatment, dermatology, translational research, and precision medicine. Located in Rome, IFO is accredited by several international organizations and is recognized for excellence in multidisciplinary patient care, advanced therapies, and scientific research.

CONTACTS
Thomas Pevenage
Investor Relations
+32 10 475 890
investorrelations@iba-group.com

Nathalie van Ypersele
Head of Communication and Sustainability

Daniel Ernult
Corporate Communication Manager
+32 10 475 890
communication@iba-group.com

---

¹ Proteus^®ONE is a brand name of Proteus^®235

Attachment

• 260929-IBA-ProteusONE-Rome-EN

Press Release

Weekly progress on share repurchase program to cover share plans and reduce capital

Kaiseraugst (Switzerland), Maastricht (Netherlands), September 29, 2026

dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 9, 2026 its intention to repurchase ordinary shares with an aggregate market value of €500 million and reduce its issued capital. On March 12, 2026, the company commenced repurchasing ordinary shares for a total amount of €540 million, of which €40 million to cover commitments under the Group’s share-based compensation plans and €500 million to reduce its issued capital.

In accordance with regulations, dsm-firmenich informs the market that during the period from September 21, 2026 up to and including September 25, 2026 a total number of 313,835 shares have been repurchased on its behalf. The shares were repurchased at an average price of €96.45 per share for a total amount of €30.3 million. The total number of shares repurchased under this program to date is 6,976,047 shares at an average price of €74.68 for a total consideration of €520.9 million.

The buyback of €40 million worth of shares to cover commitments under the Group’s share-based compensation plans was finalized on March 23, 2026. The €500 million share repurchase program to reduce the Group’s issued capital is intended to be completed by the end of Q3 2026.

For more detailed information see ‘Daily transaction details Share Repurchase Program announced February 9, 2026’.

For more information, please contact:

dsm-firmenich investor relations enquiries:
Email: investors@dsm-firmenich.com

dsm-firmenich media enquiries:
Email: media@dsm-firmenich.com   

About dsm-firmenich
As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for people and the planet. dsm-firmenich is a Swiss company, listed on Euronext Amsterdam and SIX Swiss Exchange, with operations in almost 60 countries and revenues of more than €9 billion for its Continuing Operations following the divestment of Animal Nutrition & Health. With a diverse, worldwide team of nearly 21,000 employees, we bring progress to life every day, everywhere, for billions of people. www.dsm-firmenich.com

Disclaimer  

This press release does not constitute or form part of, an offer or any solicitation of an offer for securities in any jurisdiction. This press release may contain forward-looking statements with respect to dsm-firmenich’s future. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. dsm-firmenich has no obligation to update the statements contained in this press release, unless required by law. This communication contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. The English language version of this press release prevails over other language versions.

Attachment

• Press release dsm-firmenich Progress on share repurchase program_20260929_FINAL

Press Release

Weekly progress on share repurchase program to cover share plans and reduce capital

Kaiseraugst (Switzerland), Maastricht (Netherlands), September 29, 2026

dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 9, 2026 its intention to repurchase ordinary shares with an aggregate market value of €500 million and reduce its issued capital. On March 12, 2026, the company commenced repurchasing ordinary shares for a total amount of €540 million, of which €40 million to cover commitments under the Group’s share-based compensation plans and €500 million to reduce its issued capital.

In accordance with regulations, dsm-firmenich informs the market that during the period from September 21, 2026 up to and including September 25, 2026 a total number of 313,835 shares have been repurchased on its behalf. The shares were repurchased at an average price of €96.45 per share for a total amount of €30.3 million. The total number of shares repurchased under this program to date is 6,976,047 shares at an average price of €74.68 for a total consideration of €520.9 million.

The buyback of €40 million worth of shares to cover commitments under the Group’s share-based compensation plans was finalized on March 23, 2026. The €500 million share repurchase program to reduce the Group’s issued capital is intended to be completed by the end of Q3 2026.

For more detailed information see ‘Daily transaction details Share Repurchase Program announced February 9, 2026’.

For more information, please contact:

dsm-firmenich investor relations enquiries:
Email: investors@dsm-firmenich.com

dsm-firmenich media enquiries:
Email: media@dsm-firmenich.com   

About dsm-firmenich
As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for people and the planet. dsm-firmenich is a Swiss company, listed on Euronext Amsterdam and SIX Swiss Exchange, with operations in almost 60 countries and revenues of more than €9 billion for its Continuing Operations following the divestment of Animal Nutrition & Health. With a diverse, worldwide team of nearly 21,000 employees, we bring progress to life every day, everywhere, for billions of people. www.dsm-firmenich.com

Disclaimer  

This press release does not constitute or form part of, an offer or any solicitation of an offer for securities in any jurisdiction. This press release may contain forward-looking statements with respect to dsm-firmenich’s future. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. dsm-firmenich has no obligation to update the statements contained in this press release, unless required by law. This communication contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. The English language version of this press release prevails over other language versions.

Attachment

• Press release dsm-firmenich Progress on share repurchase program_20260929_FINAL

• HRS-1596 is a phase 1-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing            
• Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties

Bagsværd, Denmark, 29 September 2026 – Novo Nordisk today announced that it has entered into a license agreement with Hengrui Pharma (600276.SH; 01276.HK) for HRS-1596, a phase 1-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist, with potential for once-weekly oral dosing.

Under the terms of the agreement, Novo will obtain exclusive rights to develop, manufacture and commercialise HRS-1596 globally, excluding mainland China, Hong Kong, Macao and Taiwan. The potential total value of the agreement is up to 2.6 billion US dollars contingent on the achievement of applicable development, regulatory and commercial milestones. This includes a 300 million dollars upfront payment. In addition, Hengrui Pharma is eligible to receive royalties based on net sales of HRS-1596 within the licensed territory.

“Novo has pioneered the field of oral peptides and as leaders, we continuously look to advance our broad and deep oral pipeline across obesity, diabetes and other cardiometabolic diseases through our strong internal capabilities and leading external innovation,” said Martin Holst Lange, executive vice president, Research & Development and chief scientific officer at Novo. “Hengrui Pharma has a proven track record of discovering and advancing innovative therapies with the patients in the center, and we are excited to add HRS-1596 to our growing pipeline and to explore its potential to raise the bar for convenience in the field.”

“We are committed to continuous innovation, bringing better treatments to patients. HRS-1596 reflects this commitment in metabolic diseases, with the potential to offer the convenience of once-weekly oral administration,” said Frank Jiang, MD, Ph.D., Executive Vice President and Chief Strategy Officer of Hengrui Pharma. “This collaboration brings together Hengrui’s innovation strengths and Novo’s global leadership in GLP-1 therapies and obesity care. Together, we aim to advance this innovative therapy for patients worldwide.”

HRS-1596 is designed to reduce weight and improve glycemic control through multiple mechanisms, including appetite suppression, stimulation of insulin secretion, and improved insulin sensitivity, supporting its potential use in obesity, type 2 diabetes, and other metabolic diseases. HRS-1596 has potential to be developed for once-weekly oral administration, which would substantially reduce dosing frequency and improve convenience compared with current offerings. Hengrui Pharma has received approval in China to initiate phase 1 clinical trials with HRS-1596 for weight management and type 2 diabetes.

The license agreement is subject to clearance under the U.S. Hart-Scott-Rodino Antitrust Improvements Act and the satisfaction of other customary closing conditions. The transaction is expected to close in the fourth quarter of 2026.

About Hengrui Pharma
Hengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Driven by a patient-focused philosophy since its founding in 1970, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology. For more information, visit us at Hengrui.com and follow us on LinkedIn.

About Novo
Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube. 

Contacts for further information

Novo Media:
Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com	Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com
Novo Investors:
Michael Novod +45 3075 6050 nvno@novonordisk.com	Sina Meyer +45 3079 6656 azey@novonordisk.com
Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com	Max Ung +45 3077 6414 mxun@novonordisk.com
Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com	Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com
Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com	Alex Bruce (US) +1 640 230 0276 axeu@novonordisk.com

Attachment

• PR260929-Hengrui

• HRS-1596 is a phase 1-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing            
• Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties

Bagsværd, Denmark, 29 September 2026 – Novo Nordisk today announced that it has entered into a license agreement with Hengrui Pharma (600276.SH; 01276.HK) for HRS-1596, a phase 1-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist, with potential for once-weekly oral dosing.

Under the terms of the agreement, Novo will obtain exclusive rights to develop, manufacture and commercialise HRS-1596 globally, excluding mainland China, Hong Kong, Macao and Taiwan. The potential total value of the agreement is up to 2.6 billion US dollars contingent on the achievement of applicable development, regulatory and commercial milestones. This includes a 300 million dollars upfront payment. In addition, Hengrui Pharma is eligible to receive royalties based on net sales of HRS-1596 within the licensed territory.

“Novo has pioneered the field of oral peptides and as leaders, we continuously look to advance our broad and deep oral pipeline across obesity, diabetes and other cardiometabolic diseases through our strong internal capabilities and leading external innovation,” said Martin Holst Lange, executive vice president, Research & Development and chief scientific officer at Novo. “Hengrui Pharma has a proven track record of discovering and advancing innovative therapies with the patients in the center, and we are excited to add HRS-1596 to our growing pipeline and to explore its potential to raise the bar for convenience in the field.”

“We are committed to continuous innovation, bringing better treatments to patients. HRS-1596 reflects this commitment in metabolic diseases, with the potential to offer the convenience of once-weekly oral administration,” said Frank Jiang, MD, Ph.D., Executive Vice President and Chief Strategy Officer of Hengrui Pharma. “This collaboration brings together Hengrui’s innovation strengths and Novo’s global leadership in GLP-1 therapies and obesity care. Together, we aim to advance this innovative therapy for patients worldwide.”

HRS-1596 is designed to reduce weight and improve glycemic control through multiple mechanisms, including appetite suppression, stimulation of insulin secretion, and improved insulin sensitivity, supporting its potential use in obesity, type 2 diabetes, and other metabolic diseases. HRS-1596 has potential to be developed for once-weekly oral administration, which would substantially reduce dosing frequency and improve convenience compared with current offerings. Hengrui Pharma has received approval in China to initiate phase 1 clinical trials with HRS-1596 for weight management and type 2 diabetes.

The license agreement is subject to clearance under the U.S. Hart-Scott-Rodino Antitrust Improvements Act and the satisfaction of other customary closing conditions. The transaction is expected to close in the fourth quarter of 2026.

About Hengrui Pharma
Hengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Driven by a patient-focused philosophy since its founding in 1970, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology. For more information, visit us at Hengrui.com and follow us on LinkedIn.

About Novo
Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube. 

Contacts for further information

Novo Media:
Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com	Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com
Novo Investors:
Michael Novod +45 3075 6050 nvno@novonordisk.com	Sina Meyer +45 3079 6656 azey@novonordisk.com
Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com	Max Ung +45 3077 6414 mxun@novonordisk.com
Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com	Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com
Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com	Alex Bruce (US) +1 640 230 0276 axeu@novonordisk.com

Attachment

• PR260929-Hengrui

• HRS-1596 is a phase 1-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing            
• Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties

Bagsværd, Denmark, 29 September 2026 – Novo Nordisk today announced that it has entered into a license agreement with Hengrui Pharma (600276.SH; 01276.HK) for HRS-1596, a phase 1-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist, with potential for once-weekly oral dosing.

Under the terms of the agreement, Novo will obtain exclusive rights to develop, manufacture and commercialise HRS-1596 globally, excluding mainland China, Hong Kong, Macao and Taiwan. The potential total value of the agreement is up to 2.6 billion US dollars contingent on the achievement of applicable development, regulatory and commercial milestones. This includes a 300 million dollars upfront payment. In addition, Hengrui Pharma is eligible to receive royalties based on net sales of HRS-1596 within the licensed territory.

“Novo has pioneered the field of oral peptides and as leaders, we continuously look to advance our broad and deep oral pipeline across obesity, diabetes and other cardiometabolic diseases through our strong internal capabilities and leading external innovation,” said Martin Holst Lange, executive vice president, Research & Development and chief scientific officer at Novo. “Hengrui Pharma has a proven track record of discovering and advancing innovative therapies with the patients in the center, and we are excited to add HRS-1596 to our growing pipeline and to explore its potential to raise the bar for convenience in the field.”

“We are committed to continuous innovation, bringing better treatments to patients. HRS-1596 reflects this commitment in metabolic diseases, with the potential to offer the convenience of once-weekly oral administration,” said Frank Jiang, MD, Ph.D., Executive Vice President and Chief Strategy Officer of Hengrui Pharma. “This collaboration brings together Hengrui’s innovation strengths and Novo’s global leadership in GLP-1 therapies and obesity care. Together, we aim to advance this innovative therapy for patients worldwide.”

HRS-1596 is designed to reduce weight and improve glycemic control through multiple mechanisms, including appetite suppression, stimulation of insulin secretion, and improved insulin sensitivity, supporting its potential use in obesity, type 2 diabetes, and other metabolic diseases. HRS-1596 has potential to be developed for once-weekly oral administration, which would substantially reduce dosing frequency and improve convenience compared with current offerings. Hengrui Pharma has received approval in China to initiate phase 1 clinical trials with HRS-1596 for weight management and type 2 diabetes.

The license agreement is subject to clearance under the U.S. Hart-Scott-Rodino Antitrust Improvements Act and the satisfaction of other customary closing conditions. The transaction is expected to close in the fourth quarter of 2026.

About Hengrui Pharma
Hengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Driven by a patient-focused philosophy since its founding in 1970, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology. For more information, visit us at Hengrui.com and follow us on LinkedIn.

About Novo
Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube. 

Contacts for further information

Novo Media:
Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com	Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com
Novo Investors:
Michael Novod +45 3075 6050 nvno@novonordisk.com	Sina Meyer +45 3079 6656 azey@novonordisk.com
Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com	Max Ung +45 3077 6414 mxun@novonordisk.com
Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com	Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com
Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com	Alex Bruce (US) +1 640 230 0276 axeu@novonordisk.com

Attachment

• PR260929-Hengrui

HANOI, Vietnam, Sept. 29, 2026 (GLOBE NEWSWIRE) — EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading Advanced Air Mobility (AAM) technology platform company, today announced that its Global Fast Track Program has expanded to Vietnam: Vietnam has become the second country to join the Program following Sri Lanka, with Hanoi as its first stop, marking EHang’s first city‑level partnership in the country. The Company’s partner, HungViet Technology and Investment Trading JSC (“HungViet”), has signed a Memorandum of Understanding (MOU) with the Hanoi Department of Science and Technology (“Hanoi DOST”) in Hanoi. In accordance with Hanoi’s dedicated procedures for regulatory sandbox testing, the parties will carry out low‑altitude economy sandbox testing of electric vertical take-off and landing (“eVTOL”) aircraft centered on the EH216‑S pilotless human‑carrying aircraft, exploring compliant validation pathways for safe operations. EHang will provide the EH216‑S aircraft and its technological systems in support of the sandbox testing.

(Photo: Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee; Cu Ngoc Trang, Director of Hanoi Department of Science and Technology, alongside relevant competent officials; Conor Yang, Chief Financial Officer of EHang; Dang Duc Dung, President & CEO of HungViet, and other representatives attended the signing ceremony.)

(Photo: Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee delivers remarks at the signing ceremony.)

Under the MOU, the Hanoi DOST will provide guidance for the application and approval of the sandbox testing, while HungViet, as the local implementing entity, will commit technical, financial and human resources starting from October 2026, prepare the sandbox application materials, and carry out controlled test flights upon receipt of the authorization decision. The EH216‑S pilotless human‑carrying aircraft, operational technology systems and personnel training support involved in the sandbox testing will be provided by EHang. Centered on the sandbox testing, the cooperation will advance in phases at Hoa Lac Hi-Tech Park: conducting controlled test flights of the EH216‑S, building an unmanned aircraft traffic management (UTM) model and an operations control center (OCC) model, while advancing operational technology training, the joint development of technical standards and regulations, and technical exchanges. The sandbox testing will proceed upon completion of the relevant application and approval procedures.

Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee, stated, “Hanoi is in a phase of rapid urban development, and the low‑altitude economy holds tremendous potential. We greatly appreciate EHang’s technical support and collaboration. The signing and execution of this project will strongly advance the development of Hanoi’s low‑altitude economy and science‑innovation industries, drive comprehensive urban development, and ultimately bring benefits to Hanoi residents. Innovative technologies such as pilotless aerial vehicles will also open brand‑new possibilities for Hanoi’s urban mobility and cultural‑tourism growth.”

Under the cooperation plan, the parties will start with regulatory sandbox testing and carry out phased technical verification of the human‑carrying and cargo‑carrying variants of the EH216‑series pilotless eVTOL aircraft in line with Vietnam’s local regulatory rules, real-world operating environments and business implementation conditions, steadily advancing commercial‑operation‑related work. Beyond Hanoi, EHang plans to further expand its business to key Vietnamese cities including Ho Chi Minh City and Da Nang, and to realize diversified commercial‑use scenarios centered around urban commuting and the development of popular tourist destinations.

Anchoring Southeast Asia as a Strategic Hub: EHang Accelerates Implementation of its Global Fast Track Program

On the sidelines of the 61st Conference of Directors General of Civil Aviation, Asia and Pacific Regions (DGCA/61), EHang held discussions with senior representatives of Malaysia’s civil aviation authority, as well as civil aviation directors and delegates from Laos, Fiji, Cambodia, the Philippines, Tonga, Vietnam, Maldives, Bhutan, Nepal and other countries. Participants explored viable paths to deploy regulatory sandbox mechanisms and the Fast Track Program within respective jurisdictions.

Vietnam’s cultural‑tourism market boasts strong growth momentum. According to official Vietnamese statistics, the country received nearly 21.2 million international inbound tourists in 2025, hitting an all‑time high. The booming tourism industry unlocks extensive market space for applications including pilotless eVTOL aerial sightseeing and urban low‑altitude mobility. The signing of the MOU in Hanoi also represents a key advance for EHang’s Global Fast Track Program in Southeast Asia.

Conor Yang, Chief Financial Officer of EHang, commented, “Expanding into overseas markets means far more than exporting aircraft hardware. What matters most is the deep alignment of technology and commercial operations with local regulatory systems. Safety and compliance are the bedrock for the commercial realization of AAM. EHang’s Global Fast Track Program is designed for the regulatory frameworks and market characteristics of individual countries and regions. Through sandbox testing, operational validation and collaboration with local partners, it connects technology, commercial operations and regulation to accelerate commercial roll‑out. Vietnam is a highly innovative and important market within ASEAN. We look forward to working solidly with the Hanoi government on testing and validation activities, accumulating valuable practical experience for the safe and orderly commercial deployment of pilotless eVTOL in the country, and advancing commercial opportunities for low‑altitude mobility across Southeast Asia.”

About EHang
EHang (Nasdaq: EH) is a global‑leading Advanced Air Mobility technology platform company dedicated to making safe, autonomous and eco‑friendly air mobility accessible to everyone. EHang focuses on the research, development and manufacturing of a diversified portfolio of pilotless electric vertical take‑off and landing (eVTOL) aerial vehicles, covering a wide range of application scenarios including aerial tourism, intra‑city commuting, inter‑city travel, logistics transportation and emergency firefighting. EHang’s flagship product, the EH216‑S, has obtained the world’s first type certificate (TC), production certificate (PC) and standard airworthiness certificate (AC) for pilotless passenger‑carrying eVTOL aircraft issued by the Civil Aviation Administration of China (CAAC), and has entered operation under China’s first batch of commercial operation qualifications for pilotless passenger‑carrying eVTOL. In addition, the Company’s long‑range VT35 model further extends inter‑city mobility scenarios, laying the foundation for a multi‑tiered low‑altitude mobility network. Leveraging its advanced autonomous flight technology and scalable operational infrastructure, EHang is redefining the transportation of people and goods — transcending cities, regions and natural barriers to usher in a new era of air mobility. For more information, please visit www.ehang.com.

Safe Harbor Statement
This press release may contain forward‑looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward‑looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “may” and other similar expressions. Statements that are not historical facts, including statements regarding management’s beliefs and expectations, are forward‑looking statements. Forward‑looking statements involve inherent risks and uncertainties. Many factors could cause actual results to differ materially from those contained in any forward‑looking statement, including but not limited to product certification, the Company’s expectations regarding demand for and market acceptance of its products, the commercialization of the Company’s autonomous aerial vehicle products and solutions and Advanced Air Mobility services, its relationships with strategic partners, and the litigation currently involving the Company and potential litigation. The Company’s management has made such forward‑looking statements based on current expectations, assumptions, estimates and projections. While the Company’s management believes that these expectations, assumptions, estimates and projections are reasonable, forward‑looking statements are only predictions of future events and involve known and unknown risks and uncertainties that are difficult for the Company’s management to control. These risks and uncertainties may cause EHang’s actual results of operations, performance or achievements to differ materially from those expressed or implied by any forward‑looking statements.

Media Contact: pr@ehang.com 
Investor Contact: ir@ehang.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/4953a6d8-2bb3-4bc3-a9a5-ec21eb70c8cc

https://www.globenewswire.com/NewsRoom/AttachmentNg/5eff6620-8226-46c4-aa87-4b0ebbb91363

HANOI, Vietnam, Sept. 29, 2026 (GLOBE NEWSWIRE) — EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading Advanced Air Mobility (AAM) technology platform company, today announced that its Global Fast Track Program has expanded to Vietnam: Vietnam has become the second country to join the Program following Sri Lanka, with Hanoi as its first stop, marking EHang’s first city‑level partnership in the country. The Company’s partner, HungViet Technology and Investment Trading JSC (“HungViet”), has signed a Memorandum of Understanding (MOU) with the Hanoi Department of Science and Technology (“Hanoi DOST”) in Hanoi. In accordance with Hanoi’s dedicated procedures for regulatory sandbox testing, the parties will carry out low‑altitude economy sandbox testing of electric vertical take-off and landing (“eVTOL”) aircraft centered on the EH216‑S pilotless human‑carrying aircraft, exploring compliant validation pathways for safe operations. EHang will provide the EH216‑S aircraft and its technological systems in support of the sandbox testing.

(Photo: Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee; Cu Ngoc Trang, Director of Hanoi Department of Science and Technology, alongside relevant competent officials; Conor Yang, Chief Financial Officer of EHang; Dang Duc Dung, President & CEO of HungViet, and other representatives attended the signing ceremony.)

(Photo: Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee delivers remarks at the signing ceremony.)

Under the MOU, the Hanoi DOST will provide guidance for the application and approval of the sandbox testing, while HungViet, as the local implementing entity, will commit technical, financial and human resources starting from October 2026, prepare the sandbox application materials, and carry out controlled test flights upon receipt of the authorization decision. The EH216‑S pilotless human‑carrying aircraft, operational technology systems and personnel training support involved in the sandbox testing will be provided by EHang. Centered on the sandbox testing, the cooperation will advance in phases at Hoa Lac Hi-Tech Park: conducting controlled test flights of the EH216‑S, building an unmanned aircraft traffic management (UTM) model and an operations control center (OCC) model, while advancing operational technology training, the joint development of technical standards and regulations, and technical exchanges. The sandbox testing will proceed upon completion of the relevant application and approval procedures.

Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee, stated, “Hanoi is in a phase of rapid urban development, and the low‑altitude economy holds tremendous potential. We greatly appreciate EHang’s technical support and collaboration. The signing and execution of this project will strongly advance the development of Hanoi’s low‑altitude economy and science‑innovation industries, drive comprehensive urban development, and ultimately bring benefits to Hanoi residents. Innovative technologies such as pilotless aerial vehicles will also open brand‑new possibilities for Hanoi’s urban mobility and cultural‑tourism growth.”

Under the cooperation plan, the parties will start with regulatory sandbox testing and carry out phased technical verification of the human‑carrying and cargo‑carrying variants of the EH216‑series pilotless eVTOL aircraft in line with Vietnam’s local regulatory rules, real-world operating environments and business implementation conditions, steadily advancing commercial‑operation‑related work. Beyond Hanoi, EHang plans to further expand its business to key Vietnamese cities including Ho Chi Minh City and Da Nang, and to realize diversified commercial‑use scenarios centered around urban commuting and the development of popular tourist destinations.

Anchoring Southeast Asia as a Strategic Hub: EHang Accelerates Implementation of its Global Fast Track Program

On the sidelines of the 61st Conference of Directors General of Civil Aviation, Asia and Pacific Regions (DGCA/61), EHang held discussions with senior representatives of Malaysia’s civil aviation authority, as well as civil aviation directors and delegates from Laos, Fiji, Cambodia, the Philippines, Tonga, Vietnam, Maldives, Bhutan, Nepal and other countries. Participants explored viable paths to deploy regulatory sandbox mechanisms and the Fast Track Program within respective jurisdictions.

Vietnam’s cultural‑tourism market boasts strong growth momentum. According to official Vietnamese statistics, the country received nearly 21.2 million international inbound tourists in 2025, hitting an all‑time high. The booming tourism industry unlocks extensive market space for applications including pilotless eVTOL aerial sightseeing and urban low‑altitude mobility. The signing of the MOU in Hanoi also represents a key advance for EHang’s Global Fast Track Program in Southeast Asia.

Conor Yang, Chief Financial Officer of EHang, commented, “Expanding into overseas markets means far more than exporting aircraft hardware. What matters most is the deep alignment of technology and commercial operations with local regulatory systems. Safety and compliance are the bedrock for the commercial realization of AAM. EHang’s Global Fast Track Program is designed for the regulatory frameworks and market characteristics of individual countries and regions. Through sandbox testing, operational validation and collaboration with local partners, it connects technology, commercial operations and regulation to accelerate commercial roll‑out. Vietnam is a highly innovative and important market within ASEAN. We look forward to working solidly with the Hanoi government on testing and validation activities, accumulating valuable practical experience for the safe and orderly commercial deployment of pilotless eVTOL in the country, and advancing commercial opportunities for low‑altitude mobility across Southeast Asia.”

About EHang
EHang (Nasdaq: EH) is a global‑leading Advanced Air Mobility technology platform company dedicated to making safe, autonomous and eco‑friendly air mobility accessible to everyone. EHang focuses on the research, development and manufacturing of a diversified portfolio of pilotless electric vertical take‑off and landing (eVTOL) aerial vehicles, covering a wide range of application scenarios including aerial tourism, intra‑city commuting, inter‑city travel, logistics transportation and emergency firefighting. EHang’s flagship product, the EH216‑S, has obtained the world’s first type certificate (TC), production certificate (PC) and standard airworthiness certificate (AC) for pilotless passenger‑carrying eVTOL aircraft issued by the Civil Aviation Administration of China (CAAC), and has entered operation under China’s first batch of commercial operation qualifications for pilotless passenger‑carrying eVTOL. In addition, the Company’s long‑range VT35 model further extends inter‑city mobility scenarios, laying the foundation for a multi‑tiered low‑altitude mobility network. Leveraging its advanced autonomous flight technology and scalable operational infrastructure, EHang is redefining the transportation of people and goods — transcending cities, regions and natural barriers to usher in a new era of air mobility. For more information, please visit www.ehang.com.

Safe Harbor Statement
This press release may contain forward‑looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward‑looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “may” and other similar expressions. Statements that are not historical facts, including statements regarding management’s beliefs and expectations, are forward‑looking statements. Forward‑looking statements involve inherent risks and uncertainties. Many factors could cause actual results to differ materially from those contained in any forward‑looking statement, including but not limited to product certification, the Company’s expectations regarding demand for and market acceptance of its products, the commercialization of the Company’s autonomous aerial vehicle products and solutions and Advanced Air Mobility services, its relationships with strategic partners, and the litigation currently involving the Company and potential litigation. The Company’s management has made such forward‑looking statements based on current expectations, assumptions, estimates and projections. While the Company’s management believes that these expectations, assumptions, estimates and projections are reasonable, forward‑looking statements are only predictions of future events and involve known and unknown risks and uncertainties that are difficult for the Company’s management to control. These risks and uncertainties may cause EHang’s actual results of operations, performance or achievements to differ materially from those expressed or implied by any forward‑looking statements.

Media Contact: pr@ehang.com 
Investor Contact: ir@ehang.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/4953a6d8-2bb3-4bc3-a9a5-ec21eb70c8cc

https://www.globenewswire.com/NewsRoom/AttachmentNg/5eff6620-8226-46c4-aa87-4b0ebbb91363

HANOI, Vietnam, Sept. 29, 2026 (GLOBE NEWSWIRE) — EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading Advanced Air Mobility (AAM) technology platform company, today announced that its Global Fast Track Program has expanded to Vietnam: Vietnam has become the second country to join the Program following Sri Lanka, with Hanoi as its first stop, marking EHang’s first city‑level partnership in the country. The Company’s partner, HungViet Technology and Investment Trading JSC (“HungViet”), has signed a Memorandum of Understanding (MOU) with the Hanoi Department of Science and Technology (“Hanoi DOST”) in Hanoi. In accordance with Hanoi’s dedicated procedures for regulatory sandbox testing, the parties will carry out low‑altitude economy sandbox testing of electric vertical take-off and landing (“eVTOL”) aircraft centered on the EH216‑S pilotless human‑carrying aircraft, exploring compliant validation pathways for safe operations. EHang will provide the EH216‑S aircraft and its technological systems in support of the sandbox testing.

(Photo: Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee; Cu Ngoc Trang, Director of Hanoi Department of Science and Technology, alongside relevant competent officials; Conor Yang, Chief Financial Officer of EHang; Dang Duc Dung, President & CEO of HungViet, and other representatives attended the signing ceremony.)

(Photo: Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee delivers remarks at the signing ceremony.)

Under the MOU, the Hanoi DOST will provide guidance for the application and approval of the sandbox testing, while HungViet, as the local implementing entity, will commit technical, financial and human resources starting from October 2026, prepare the sandbox application materials, and carry out controlled test flights upon receipt of the authorization decision. The EH216‑S pilotless human‑carrying aircraft, operational technology systems and personnel training support involved in the sandbox testing will be provided by EHang. Centered on the sandbox testing, the cooperation will advance in phases at Hoa Lac Hi-Tech Park: conducting controlled test flights of the EH216‑S, building an unmanned aircraft traffic management (UTM) model and an operations control center (OCC) model, while advancing operational technology training, the joint development of technical standards and regulations, and technical exchanges. The sandbox testing will proceed upon completion of the relevant application and approval procedures.

Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee, stated, “Hanoi is in a phase of rapid urban development, and the low‑altitude economy holds tremendous potential. We greatly appreciate EHang’s technical support and collaboration. The signing and execution of this project will strongly advance the development of Hanoi’s low‑altitude economy and science‑innovation industries, drive comprehensive urban development, and ultimately bring benefits to Hanoi residents. Innovative technologies such as pilotless aerial vehicles will also open brand‑new possibilities for Hanoi’s urban mobility and cultural‑tourism growth.”

Under the cooperation plan, the parties will start with regulatory sandbox testing and carry out phased technical verification of the human‑carrying and cargo‑carrying variants of the EH216‑series pilotless eVTOL aircraft in line with Vietnam’s local regulatory rules, real-world operating environments and business implementation conditions, steadily advancing commercial‑operation‑related work. Beyond Hanoi, EHang plans to further expand its business to key Vietnamese cities including Ho Chi Minh City and Da Nang, and to realize diversified commercial‑use scenarios centered around urban commuting and the development of popular tourist destinations.

Anchoring Southeast Asia as a Strategic Hub: EHang Accelerates Implementation of its Global Fast Track Program

On the sidelines of the 61st Conference of Directors General of Civil Aviation, Asia and Pacific Regions (DGCA/61), EHang held discussions with senior representatives of Malaysia’s civil aviation authority, as well as civil aviation directors and delegates from Laos, Fiji, Cambodia, the Philippines, Tonga, Vietnam, Maldives, Bhutan, Nepal and other countries. Participants explored viable paths to deploy regulatory sandbox mechanisms and the Fast Track Program within respective jurisdictions.

Vietnam’s cultural‑tourism market boasts strong growth momentum. According to official Vietnamese statistics, the country received nearly 21.2 million international inbound tourists in 2025, hitting an all‑time high. The booming tourism industry unlocks extensive market space for applications including pilotless eVTOL aerial sightseeing and urban low‑altitude mobility. The signing of the MOU in Hanoi also represents a key advance for EHang’s Global Fast Track Program in Southeast Asia.

Conor Yang, Chief Financial Officer of EHang, commented, “Expanding into overseas markets means far more than exporting aircraft hardware. What matters most is the deep alignment of technology and commercial operations with local regulatory systems. Safety and compliance are the bedrock for the commercial realization of AAM. EHang’s Global Fast Track Program is designed for the regulatory frameworks and market characteristics of individual countries and regions. Through sandbox testing, operational validation and collaboration with local partners, it connects technology, commercial operations and regulation to accelerate commercial roll‑out. Vietnam is a highly innovative and important market within ASEAN. We look forward to working solidly with the Hanoi government on testing and validation activities, accumulating valuable practical experience for the safe and orderly commercial deployment of pilotless eVTOL in the country, and advancing commercial opportunities for low‑altitude mobility across Southeast Asia.”

About EHang
EHang (Nasdaq: EH) is a global‑leading Advanced Air Mobility technology platform company dedicated to making safe, autonomous and eco‑friendly air mobility accessible to everyone. EHang focuses on the research, development and manufacturing of a diversified portfolio of pilotless electric vertical take‑off and landing (eVTOL) aerial vehicles, covering a wide range of application scenarios including aerial tourism, intra‑city commuting, inter‑city travel, logistics transportation and emergency firefighting. EHang’s flagship product, the EH216‑S, has obtained the world’s first type certificate (TC), production certificate (PC) and standard airworthiness certificate (AC) for pilotless passenger‑carrying eVTOL aircraft issued by the Civil Aviation Administration of China (CAAC), and has entered operation under China’s first batch of commercial operation qualifications for pilotless passenger‑carrying eVTOL. In addition, the Company’s long‑range VT35 model further extends inter‑city mobility scenarios, laying the foundation for a multi‑tiered low‑altitude mobility network. Leveraging its advanced autonomous flight technology and scalable operational infrastructure, EHang is redefining the transportation of people and goods — transcending cities, regions and natural barriers to usher in a new era of air mobility. For more information, please visit www.ehang.com.

Safe Harbor Statement
This press release may contain forward‑looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward‑looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “may” and other similar expressions. Statements that are not historical facts, including statements regarding management’s beliefs and expectations, are forward‑looking statements. Forward‑looking statements involve inherent risks and uncertainties. Many factors could cause actual results to differ materially from those contained in any forward‑looking statement, including but not limited to product certification, the Company’s expectations regarding demand for and market acceptance of its products, the commercialization of the Company’s autonomous aerial vehicle products and solutions and Advanced Air Mobility services, its relationships with strategic partners, and the litigation currently involving the Company and potential litigation. The Company’s management has made such forward‑looking statements based on current expectations, assumptions, estimates and projections. While the Company’s management believes that these expectations, assumptions, estimates and projections are reasonable, forward‑looking statements are only predictions of future events and involve known and unknown risks and uncertainties that are difficult for the Company’s management to control. These risks and uncertainties may cause EHang’s actual results of operations, performance or achievements to differ materially from those expressed or implied by any forward‑looking statements.

Media Contact: pr@ehang.com 
Investor Contact: ir@ehang.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/4953a6d8-2bb3-4bc3-a9a5-ec21eb70c8cc

https://www.globenewswire.com/NewsRoom/AttachmentNg/5eff6620-8226-46c4-aa87-4b0ebbb91363

• Affiliate partnership with Redbrick Mortgage Advisory gives SingSaver users bank-by-bank rate comparison and advice through to application
• The launch takes SingSaver into Singapore’s largest household debt category, worth S$296.4 billion, where the gap between bank home loan rates and the HDB concessionary rate of 2.6% can add up to hundreds of dollars a month for borrowers

SINGAPORE, Sept. 29, 2026 (GLOBE NEWSWIRE) — SingSaver, Singapore’s leading personal finance comparison platform and part of Nasdaq-listed MoneyHero Group (NASDAQ: MNY), today launched a Home Loans comparison category in partnership with Redbrick Mortgage Advisory. The launch takes SingSaver into the largest category of household debt in Singapore and extends its product suite beyond credit cards, personal loans, insurance and brokerage.

Under the partnership, SingSaver contributes its brand and high-intent user base, connecting Singaporeans researching home loans with Redbrick’s comparison and advisory service. Redbrick manages the underlying bank panel and broker relationships, handling the process from comparison through to application.

Home loans represent Singapore’s single largest household debt category. Outstanding home loans reached S$296.4 billion in the first quarter of 2026. This accounted for approximately 71% of total household debt. The balance has grown for ten consecutive quarters, according to data released by the Department of Statistics (SingStat) and the Monetary Authority of Singapore (MAS).

A Shifting Rate Environment

The partnership lands at a point when the cost of not comparing has become easy to quantify. Three-month compounded Singapore Overnight Rate Average (SORA), the benchmark banks use to price most floating-rate mortgages, stood around 1.19% in mid-September 2026. Bank mortgage packages have followed suit, with rates across major lenders now well below the HDB concessionary rate of 2.6%, which has not changed since Q2 of 2026.

For a borrower with S$800,000 outstanding, the difference between 2.6% and 1.4% is roughly S$454 a month, or about S$5,400 a year. On a S$300,000 HDB loan, it is closer to S$170 a month. That arithmetic is driving a refinancing wave, concentrated among HDB flat owners whose lock-in periods have expired and who are comparing bank packages for the first time.

“Home loans are the single biggest financial commitment most Singaporeans will make, yet the market has stayed fragmented and hard to compare. Redbrick is one of the most established names in mortgage advisory in Singapore, and this partnership closes a genuine gap in our platform at a time when falling rates are pushing more homeowners to actively shop around,” said Ayush Goyal, Managing Director at SingSaver.

“Redbrick’s role has always been to give Singaporean homeowners impartial, expert guidance through one of the biggest financial decisions they will make. This partnership puts that guidance in front of a much wider pool of homeowners, right at the point they start comparing their options, and lets more people access the high standard of advice we’ve built our name on,” said Eugene Huang, Co-founder and director of Redbrick Mortgage Advisory.

The launch builds on growth SingSaver has already seen in higher-ticket lending, including its personal loans and brokerage categories, and positions the platform in one of the largest consumer lending markets in Singapore.

The Home Loans category is now live on SingSaver’s website here.

About MoneyHero Group

MoneyHero Limited (NASDAQ: MNY) is a tech- and AI-powered personal finance aggregation and comparison platform that provides consumers with actionable insights to discover, compare, and choose the best financial products with confidence — bringing data intelligence and seamless digital access across insurance and banking solutions. The Company operates in Singapore, Hong Kong, Taiwan and the Philippines. Its brand portfolio includes B2C platforms MoneyHero, SingSaver, Money101, Moneymax and Seedly, as well as the B2B platform Creatory. MoneyHero had over 280 commercial partner relationships as at June 30, 2026, and had approximately 3.7 million Monthly Unique Users across its platform for the three months ended June 30, 2026. The Company’s backers include Peter Thiel—co-founder of PayPal, Palantir Technologies, and the Founders Fund—and Hong Kong businessman, Richard Li, the founder and chairman of Pacific Century Group. To learn more about MoneyHero and how the innovative fintech company is driving APAC’s digital economy, please visit www.MoneyHeroGroup.com.

About Redbrick Mortgage Advisory

Redbrick is Singapore’s largest independent mortgage advisory firm, renowned for its expertise in financial analysis and mortgage planning concepts. The firm provides unbiased property financing, mortgage advisory, and optimization services to its clients at no cost. By partnering with all leading banking and financial institutions in Singapore, Redbrick ensures that the latest information and resources are always at its fingertips, ready to be deployed for the benefit of its clients.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbour provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated benefits of the partnership and SingSaver’s expansion into the home loans category. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. MoneyHero Group undertakes no obligation to update these statements except as required by law.

Media Contact

Ellerton & Co. on behalf of SingSaver / MoneyHero Group
moneyhero@ellerton.sg